Compare NCMI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | TNXP |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.6M | 199.7M |
| IPO Year | 2006 | 2008 |
| Metric | NCMI | TNXP |
|---|---|---|
| Price | $2.46 | $13.19 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.63 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 490.5K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | 52.17 | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $11.20 | $558.11 |
| Revenue Next Year | $6.22 | $38.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.85 |
| 52 Week Low | $2.16 | $9.40 |
| 52 Week High | $5.03 | $29.19 |
| Indicator | NCMI | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 34.71 | 55.91 |
| Support Level | $2.16 | $13.13 |
| Resistance Level | $3.74 | $14.30 |
| Average True Range (ATR) | 0.12 | 0.68 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 18.39 | 43.11 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.